−0.61USD
−16.34 MUSD
21.64 MUSD
23.14 M
About Fennec Pharmaceuticals Inc.
Sector
CEO
Rostislav C. Raykov
Headquarters
Durham
Website
Employees (FY)
29
Founded
1996
FIGI
BBG000DTH814
Fennec Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in the development of sodium thiosulfate for the prevention of ototoxicity from cisplatin in pediatric cancer patients. The company was founded by Orest W. Blaschuk on September 3, 1996 and is headquartered in Durham, NC.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Curated watchlists where FENC is featured.
Frequently Asked Questions
The current price of FENC is 9.24 USD — it has decreased by 1.49% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Fennec Pharmaceuticals Inc. stocks are traded under the ticker FENC.
Fennec Pharmaceuticals Inc. is going to release the next earnings report on May 9, 2024. Keep track of upcoming events with our Earnings Calendar.
FENC stock is 6.19% volatile and has beta coefficient of 0.61. Check out the list of the most volatile stocks — is Fennec Pharmaceuticals Inc. there?
FENC earnings for the last quarter are −0.07 USD per share, whereas the estimation was −0.12 USD resulting in a 41.67% surprise. The estimated earnings for the next quarter are −0.02 USD per share. See more details about Fennec Pharmaceuticals Inc. earnings.
Fennec Pharmaceuticals Inc. revenue for the last quarter amounts to 6.50 M USD despite the estimated figure of 5.33 M USD. In the next quarter revenue is expected to reach 8.66 M USD.
Yes, you can track Fennec Pharmaceuticals Inc. financials in yearly and quarterly reports right on TradingView.
FENC stock has fallen by 9.50% compared to the previous week, the month change is a 17.20% fall, over the last year Fennec Pharmaceuticals Inc. has showed a 20.63% increase.
FENC net income for the last quarter is −2.76 M USD, while the quarter before that showed −1.84 M USD of net income which accounts for −49.52% change. Track more Fennec Pharmaceuticals Inc. financial stats to get the full picture.
Today Fennec Pharmaceuticals Inc. has the market capitalization of 250.33 M, it has decreased by 9.76% over the last week.
No, FENC doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, FENC shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Fennec Pharmaceuticals Inc. stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 24, 2024, the company has 29.00 employees. See our rating of the largest employees — is Fennec Pharmaceuticals Inc. on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Fennec Pharmaceuticals Inc. technincal analysis shows the sell today, and its 1 week rating is neutral. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Fennec Pharmaceuticals Inc. stock shows the buy signal. See more of Fennec Pharmaceuticals Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on Fennec Pharmaceuticals Inc. future price: according to them, FENC price has a max estimate of 20.00 USD and a min estimate of 16.00 USD. Read a more detailed Fennec Pharmaceuticals Inc. forecast: see what analysts think of Fennec Pharmaceuticals Inc. and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Fennec Pharmaceuticals Inc. EBITDA is −13.00 M USD, and current EBITDA margin is −60.09%. See more stats in Fennec Pharmaceuticals Inc. financial statements.